Verona Pharma Stock Price, News & Analysis

Verona Pharma plc (Nasdaq: VRNA) presented an abstract at the American Thoracic Society International Conference in May 2022, confirming that ensifentrine met all safety objectives in a thorough QT study. The findings, which indicated no significant effects on cardiac conduction, support Verona's upcoming New Drug Application for ensifentrine as a treatment for chronic obstructive pulmonary disease (COPD). The FDA requires such studies for new drug submissions, enhancing the potential for ensifentrine's approval.

Verona Pharma (Nasdaq: VRNA) announced its participation in two key conferences in May 2022. The LifeSci Partners Virtual Immunology & Inflammation Symposium will take place on May 10 at 9:00 AM ET, and the H.C. Wainwright Hybrid Global Investment Conference is scheduled for May 24 at 3:30 PM ET in Miami. Verona Pharma is advancing its Phase 3 clinical program for nebulized ensifentrine, aimed at COPD treatment, with expected top-line data in Q3 2022. Ensifentrine could potentially be a breakthrough therapy combining bronchodilator and anti-inflammatory properties.

Verona Pharma (VRNA) reported its Q1 2022 financial results, highlighting significant progress in its Phase 3 ENHANCE clinical trials for COPD treatment, with 90% enrollment completion. The company anticipates top-line data from ENHANCE-2 in Q3 2022 and plans to submit a New Drug Application to the FDA in H1 2023, pending positive results. Cash and equivalents were $132.8 million as of March 31, 2022, expected to fund operations through 2023. However, net loss increased to $24.8 million from $21.3 million year-over-year.

Verona Pharma plc (Nasdaq: VRNA) announced it will report its financial results for Q1 2022 on May 3, 2022, followed by a conference call at 9:00 a.m. EDT. The company focuses on treatments for respiratory diseases, with its key product candidate ensifentrine undergoing Phase 3 clinical trials for COPD. Ensifentrine may offer unique bronchodilator and anti-inflammatory effects. The call can be accessed via telephone or a live webcast available on the company's website. For more details, visit www.veronapharma.com.

Verona Pharma plc (Nasdaq: VRNA) announces the appointment of Mr. James Brady as a Non-Executive Director, enhancing its board with his extensive experience in the biopharmaceutical industry. Brady's career spans over 30 years at AstraZeneca, including his role as Chief Financial Officer of MedImmune, contributing to significant product development. Concurrently, Dr. Andrew Sinclair will step down from the board after the Annual General Meeting on April 27, 2022. Verona Pharma is progressing its commercialization plans for ensifentrine, a novel respiratory therapy.

Verona Pharma (VRNA) reported financial results for Q4 and full year 2021, highlighting significant progress in the Phase 3 ENHANCE program aimed at COPD treatment. Enrollment is complete for over 800 subjects in ENHANCE-2 and approximately 400 in ENHANCE-1. Positive safety results from a TQT study were disclosed, supporting a potential NDA submission in H1 2023. Financially, the company noted a revenue of $40 million from the Nuance agreement, a net loss of $55.6 million for the year, and a cash position of $148.4 million as of December 31, 2021.

Ligand Pharmaceuticals (NASDAQ: LGND) reported strong financial results for Q4 and the full year 2021, with total revenues of $72.5 million in Q4, up from $70.0 million in 2020, and $277.1 million for the year, a significant increase from $186.4 million in 2020. Royalties rose to $17.6 million in Q4, largely due to the Pelican platform. However, net income for Q4 was a loss of $5.0 million compared to a profit of $5.8 million the previous year. Ligand plans to spin off its OmniAb business, expected to generate substantial growth, and provided guidance for 2022 revenues of $147 million to $172 million.

Verona Pharma plc (Nasdaq: VRNA) will announce its fourth quarter and full year financial results for 2021 on March 3, 2022. The company, focused on innovative therapies for respiratory diseases, will host a conference call at 9:00 a.m. EST to discuss the results and corporate updates. Interested participants can join via specified phone numbers or a live webcast available on the company's website. Verona Pharma is advancing its product candidate, ensifentrine, currently in Phase 3 and Phase 2 clinical trials, aiming to offer unique treatment options for COPD and other respiratory conditions.

Verona Pharma, a clinical-stage biopharmaceutical company, has completed the enrollment of over 800 subjects in its Phase 3 ENHANCE-2 trial, which evaluates ensifentrine for chronic obstructive pulmonary disease (COPD) maintenance treatment. The top-line data is expected in the third quarter of 2022. CEO David Zaccardelli noted that reaching this milestone during the ongoing pandemic is significant. The trial aims to demonstrate the efficacy of ensifentrine, which combines bronchodilator and anti-inflammatory effects, in improving lung function and quality of life for COPD patients.